1st Department of Psychiatry, Psychotherapy and Early Intervention, Medical University of Lublin, Głuska 1, 20-439, Lublin, Poland.
Department of Clinical Neuropsychiatry, Medical University of Lublin, 20-439, Lublin, Poland.
Nutr J. 2019 Aug 31;18(1):50. doi: 10.1186/s12937-019-0475-x.
Current treatment of major depressive disorder (MDD) often does not achieve full remission of symptoms. Therefore, new forms of treatment and/or adjunct therapy are needed. Evidence has confirmed the modulation of the gut-brain-microbiota axis as a promising approach in MDD patients. The overall purpose of the SANGUT study-a 12-week, randomized, double-blind, and placebo-controlled Study Evaluating the Effect of Probiotic Supplementation on the Mental Status, Inflammation, and Intestinal Barrier in Major Depressive Disorder Patients Using Gluten-free or Gluten-containing Diet - is to determine the effect of interventions focused on the gut-brain-microbiota axis in a group of MDD patients.
A total of 120 outpatients will be equally allocated into one of four groups: (1) probiotic supplementation+gluten-free diet group (PRO-GFD), (2) placebo supplementation+ gluten-free diet group (PLA-GFD), (3) probiotic supplementation+ gluten containing diet group (PRO-GD), and (4) placebo supplementation+gluten containing diet group (PLA-GD). PRO groups will receive a mixture of psychobiotics (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175), and GFD groups will follow a gluten-free diet. The intervention will last 12 weeks. The primary outcome measure is change in wellbeing, whereas the secondary outcome measures include physiological parameters.
Microbiota and its metabolites have the potential to influence CNS function. Probiotics may restore the eubiosis within the gut while a gluten-free diet, via changes in the microbiota profile and modulation of intestinal permeability, may alter the activity of microbiota-gut-brain axis previously found to be associated with the pathophysiology of depression. It is also noteworthy that microbiota being able to digest gluten may play a role in formation of peptides with different immunogenic capacities. Thus, the combination of a gluten-free diet and probiotic supplementation may inhibit the immune-inflammatory cascade in MDD course and improve both psychiatric and gut barrier-associated traits.
NCT03877393 .
目前,针对重度抑郁症(MDD)的治疗往往无法使症状完全缓解。因此,需要新的治疗形式和/或辅助治疗。有证据证实,调节肠道-脑-微生物群轴是 MDD 患者的一种很有前途的方法。SANGUT 研究是一项为期 12 周、随机、双盲、安慰剂对照的研究,旨在评估补充益生菌对使用无麸质或含麸质饮食的 MDD 患者的精神状态、炎症和肠道屏障的影响,该研究全面评估了干预措施对肠道-脑-微生物群轴的影响。
共有 120 名门诊患者被平均分配到四组中的一组:(1)益生菌补充剂+无麸质饮食组(PRO-GFD),(2)安慰剂补充剂+无麸质饮食组(PLA-GFD),(3)益生菌补充剂+含麸质饮食组(PRO-GD)和(4)安慰剂补充剂+含麸质饮食组(PLA-GD)。PRO 组将服用混合益生菌(瑞士乳杆菌 R0052 和长双歧杆菌 R0175),GFD 组将遵循无麸质饮食。干预将持续 12 周。主要结局指标是幸福感的变化,次要结局指标包括生理参数。
微生物群及其代谢物有可能影响中枢神经系统功能。益生菌可能通过恢复肠道内的共生状态,而无麸质饮食通过改变微生物群谱和调节肠道通透性,改变先前与抑郁症病理生理学相关的微生物群-肠道-大脑轴的活性,从而恢复肠道内的共生状态。值得注意的是,能够消化麸质的微生物可能在形成具有不同免疫原性能力的肽中发挥作用。因此,无麸质饮食和益生菌补充的结合可能会抑制 MDD 病程中的免疫炎症级联反应,并改善精神科和肠道屏障相关特征。
NCT03877393。